Inhibitors of sars-cov-2

A compound defined by any of Formula (A-1)-(A-20)

• or pharmaceutically acceptable salts or prodrugs thereof, wherein, as valence and stability permit,
• Rc is chosen from the following groups:
• A and D are independently selected from CR6, and N;
• E, G, Q, T, and U are independently selected from CR6, N, NR6, S, and O;
• Xa—Xd, and Ya—Yd are independently selected from CR6, N, NR6, N═O, S, and O;
• M is selected from C, CR6, S, and SR6;
• the dotted lines represent single or double bonds as valence and stability permit;
• Rd is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5;
• R1, R2, R3, and R4 are each individually chosen from hydrogen, hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl;
• alkylthio;
• haloalkylthio;
• alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;
• R5 is, individually for each occurrence, chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl;
• alkylthio;
• haloalkylthio;
• alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino;
• R6 is, individually for each occurrence, chosen from hydrogen, alkyl, haloalkyl;
• alkenyl, haloalkenyl, alkynyl, and haloalkynyl;
• R7 is chosen from hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, each optionally substituted with one or more substituents individually chosen from R5;
• R8 and R9 are independently selected from —NR6R6, —OH, ═O, and H, wherein at least one of R8 or R9 is selected from —NR6R6, —OH, and ═O;
• and
• R10 and R11 are independently selected from H or —OH.

A compound defined by Formula (XIII) below

• or a pharmaceutically acceptable salt or prodrug thereof, wherein, as valence and stability permit,
• Ar1 and Ar2 are independently selected from aryl or heteroaryl, each optionally substituted with one or more substituents individually chosen from R5;
• Z is optionally present, and selected from —NH(CH2)n—, —CH(CH2)n—, and —CH2(CH2)n—;
• n is an integer selected from 1 to 6;
• X is —CONH—;
• Y is optionally present and selected from aryl, heteroaryl, each optionally substituted with one or more substituents individually chosen from R5;
• R is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5;
• and
• R5 is, individually for each occurrence, chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl;
• alkylthio;
• haloalkylthio;
• alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino.

A compound defined by Formula (B-1) to Formula (B-20) below

• or pharmaceutically acceptable salts or prodrugs thereof, wherein, as valence and stability permit,
• Z is optionally present, and selected from —NH(CH2)n—, —CH(CH2)n—, and —CH2(CH2)n—;
• n is an integer selected from 1 to 6;
• X is —CONH—;
• Y is optionally present and selected from aryl, heteroaryl, each optionally substituted with one or more substituents individually chosen from R5;
• R is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5;
• R1, R2, R3, and R4 are each individually chosen from hydrogen, hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl;
• alkylthio;
• haloalkylthio;
• alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;
• and
• R5 is, individually for each occurrence, chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl;
• alkylthio;
• haloalkylthio;
• alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino;
• R6 is, individually for each occurrence, chosen from hydrogen, alkyl, haloalkyl;
• alkenyl, haloalkenyl, alkynyl, and haloalkynyl;
• R7 is chosen from hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, each optionally substituted with one or more substituents individually chosen from R5;
• R8 and R9 are independently selected from —NR6R6, —OH, ═O, and H, wherein at least one of R8 or R9 is selected from —NR6R6, —OH, and ═O;
• R11 are independently selected from H or —OH;
• Q, T, and U are independently selected from CR6, N, NR, S, and O;
• and
• Xa—Xd, and Ya—Yd are independently selected from CR6, N, NR6, N═O, S, and O.